|1.||Gan, Tong J: 17 articles (01/2014 - 04/2002)|
|2.||Freedman, Stephen B: 11 articles (02/2015 - 04/2006)|
|3.||Rudd, John A: 11 articles (08/2014 - 11/2002)|
|4.||Habib, Ashraf S: 8 articles (06/2013 - 07/2004)|
|5.||Apfel, Christian C: 7 articles (11/2013 - 01/2004)|
|6.||Johnson, Bankole A: 7 articles (09/2013 - 09/2003)|
|7.||Fujii, Yoshitaka: 7 articles (12/2011 - 01/2005)|
|8.||Parker, Linda A: 6 articles (08/2014 - 07/2004)|
|9.||Porreca, Frank: 6 articles (08/2013 - 05/2007)|
|10.||Carides, Alexandra D: 6 articles (06/2011 - 06/2002)|
01/01/1999 - "However, there was a significant reduction in emesis management costs for patients treated after versus before the availability of ondansetron: for patients treated in the last third versus first third of the study period, there was a decrease in cost per patient per month of treatment of $374 (95% confidence interval, $243 to $505). "
03/01/1996 - "The need for antiemetic rescue therapy (ondansetron 0.15 mg/kg intravenously after three episodes of emesis prior to discharge) was significantly greater in children who received placebo compared with the ondansetron 0.15 mg/kg study group (13% vs 0%, P < 0.05). "
11/01/2012 - "In conclusion, the administration of oral ondansetron to children with vomiting in the emergency department is clinically effective and results in significant economic savings."
12/01/2001 - "The incidence of vomiting was significantly greater after infusion of placebo than after either low-dose or high-dose ondansetron. "
12/01/1997 - "All doses of ondansetron 0.05 mg/kg, 0.1 mg/kg, and 0.15 mg/kg were significantly more effective than placebo in reducing the incidence of emesis prior to, following discharge, and during the first 24 postoperative hours (p < 0.001). "
|2.||Postoperative Nausea and Vomiting (PONV)
01/01/1994 - "In conclusion ondansetron given preoperatively had proven to be an effective treatment for PONV after epidural block for lower abdominal surgery."
02/01/1994 - "Clearance has been received from the Food and Drug Administration for marketing of Zofran injection for the prevention of postoperative nausea and vomiting, at a dose of 4 mg IV over 2 to 5 min. Zofran has been evaluated in clinical studies with good results in the reduction or prevention of postoperative nausea and vomiting with minimal adverse reactions."
12/01/1999 - "We evaluated the antiemetic efficacy, safety, and routine use of prophylactic ondansetron, a "gold standard" antiemetic, in women undergoing radical breast surgery who were at a high risk of postoperative vomiting. "
01/01/1999 - "Ondansetron, a selective serotonergic antagonist, is effective in reducing postoperative nausea and vomiting in several high-risk populations. "
08/01/1996 - "Ondansetron, a selective serotonergic (5-HT3) antagonist, is effective in reducing postoperative vomiting in several high-risk populations. "
03/01/2008 - "However, the latter improved nausea on day 2. A single 8 mg dose of ondansetron can maintain antiemetic efficacy in the majority of complete responders in arm A and arm B."
05/01/1994 - "The two schedules of ondansetron used in the first 24 hours were no different in their antiemetic efficacy, with similar rates for complete responses (76.7% v 72.0%, P = .472), complete plus major responses (90.2% v 82.0%, P = .135), and severity of nausea (P = .348). "
10/01/2012 - "The addition of ondansetron ODT resulted in a significant improvement in degree of nausea."
10/01/2012 - "Conversely, during phase 2, patients receiving ondansetron ODT showed significant improvement in both measures of nausea. "
07/01/2001 - "There was a significant reduction in the frequency of emetic episodes and rescue antiemetic requirement in patients treated with ondansetron; however, ondansetron did not significantly reduce the incidence of nausea alone (14% in Group 2 vs 5% in Group 1, P = .065). "
01/30/2006 - "Furthermore, the effects of ondansetron were significantly greater in cancer animals compared to shams. "
03/01/2005 - "A prospective randomized trial of the antiemetic efficacy and cost-effectiveness of intravenous and orally disintegrating tablet of ondansetron in children with cancer."
12/01/1992 - "Priestman (Eur J Cancer Clin Oncol 25:529-533, 1989 [Suppl]) reported on a pilot and randomized study with ondansetron after single doses of 8 to 10 Gy to the upper abdomen. "
12/01/1992 - "The safety of intravenous (IV) and oral ondansetron has been evaluated in over 7,000 cancer patients in world-wide clinical trials. "
01/01/1992 - "Ondansetron was given as anti-emetic prophylaxis to 429 children receiving a variety of emetogenic cancer treatments for up to 8 days, in three, open, multicentre, European studies. "
10/01/1998 - "Although under treatment with ondansetron a significant improvement of itching as assessed by the VAS score was demonstrated, this treatment was not preferred over placebo by the patients. "
03/01/1999 - "We have evaluated the efficacy of ondansetron in the prevention of opioid-induced pruritus in a prospective, randomized, double-blind, placebo-controlled study. "
11/01/2012 - "Ondansetron was demonstrated to have negligible effect on cholestatic or uremic pruritus on the basis of a limited number of studies."
11/01/2012 - "Overall, three studies showed no benefit to ondansetron over placebo; however, two studies in cholestatic pruritus showed small reductions in pruritus with questionable clinical significance. "
11/01/2012 - "Electronic databases were systematically searched for randomized controlled trials examining the role of ondansetron in cholestatic or uremic pruritus between 1966 and 2008. "
|6.||Serotonin (5 Hydroxytryptamine)
|1.||Drug Therapy (Chemotherapy)
|5.||Patient-Controlled Analgesia (Analgesia, Patient Controlled)